Aminosalicylic Acid Suppliers & Bulk Manufacturers
Available Forms: Tablets / Granules
Available Strengths: 500 mg
Reference Brands: Generic formulations marketed under different names
Category:
Antibiotics
Aminosalicylic acid is available in Tablets / Granules
and strengths such as 500 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Aminosalicylic acid is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Aminosalicylic acid can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Aminosalicylic acid, also known as para-aminosalicylic acid (PAS), is a synthetic antibiotic primarily used in the treatment of tuberculosis, especially drug-resistant forms. It is marketed under brand names such as Paser and is typically administered orally as tablets or granules. Aminosalicylic acid works by inhibiting the growth of Mycobacterium tuberculosis, interfering with bacterial folate metabolism and protein synthesis, making it effective in combination with other antituberculosis medications.
Beyond its use in tuberculosis, aminosalicylic acid has been utilized as a second-line therapy for inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease, in patients who are intolerant or unresponsive to sulfasalazine. Its pharmacological activity allows it to modulate bacterial growth in the gut while exerting anti-inflammatory effects in the intestinal mucosa.
Aminosalicylic acid remains an important therapeutic option for managing multidrug-resistant tuberculosis and certain gastrointestinal inflammatory disorders. Its inclusion in combination regimens helps improve treatment outcomes and reduce the risk of further drug resistance, ensuring effective management of these challenging clinical conditions.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing